The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. 10x Genomics Inc’s current trading price is -45.19% away from its 52-week high, while its distance from the 52-week low is 100.15%. The stock’s price range for this period has been between $6.78 and $24.76 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 7.68 million for the day, a number notably higher than the average daily volume of 3.7 million over the last three months.
At present, 10x Genomics Inc (TXG) has a stock price of $13.57. In the previous session, the stock saw a rise, peaking at $17.0 after an opening price of $13.57. The day’s lowest price was $13.0, and it closed at $12.81.
The market performance of 10x Genomics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $24.76 on 09/03/24, while the lowest value for the same duration was $6.78 on 04/07/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
10x Genomics Inc (TXG) has experienced a quarterly rise of 40.62% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.69B and boasts a workforce of 1306 employees.
10x Genomics Inc: What Analysts Are Saying
As of right now, 6 analysts are rating 10x Genomics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 8 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.32, with a change in price of +3.62. Similarly, 10x Genomics Inc recorded 3,786,903 in trading volume during the last 100 days, posting a change of +36.38%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for TXG stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.10.
TXG Stock Stochastic Average
As of today, 10x Genomics Inc’s raw stochastic average for the last 50 days stands at 77.15%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 60.74%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 41.45% and 33.27%, respectively.
TXG Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Year to date metric has recorded a loss of -33.58%.However, over the last six months, we can see a weaker performance of 14.81%. Over the last 30 days, the price of TXG has fallen by 11.05%. And in the last five days, it has surged by 7.19%.
